Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...
First In-Man Experience Exceeds Expectations, Cited as “Game Changer” for Below-the-Knee Procedures CAMBRIDGE, Mass.--(BUSINESS WIRE)--Summa Therapeutics, LLC announced today that the first-in-man ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results